Integra Lifesciences Holdings (Integra Lifesciences Holdings) Intrinsic Value: Projected FCF

: $35.47 (As of Today)

View and export this data going back to 1995. Start your Free Trial

Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company. The details of how we calculate the intrinsic value of stocks are described in detail here.

As of today (2024-04-20), Integra Lifesciences Holdings's Intrinsic Value: Projected FCF is $35.47. The stock price of Integra Lifesciences Holdings is $28.68. Therefore, Integra Lifesciences Holdings's Price-to-Intrinsic-Value-Projected-FCF of today is 0.8.

The historical rank and industry rank for Integra Lifesciences Holdings's Intrinsic Value: Projected FCF or its related term are showing as below:

IART' s Price-to-Projected-FCF Range Over the Past 10 Years
Min: 0.81 Med: 2.38 Max: 3.22
Current: 0.81

During the past 13 years, the highest Price-to-Intrinsic-Value-Projected-FCF of Integra Lifesciences Holdings was 3.22. The lowest was 0.81. And the median was 2.38.

IART's Price-to-Projected-FCF is ranked better than
78.72% of 343 companies
in the Medical Devices & Instruments industry
Industry Median: 1.64 vs IART: 0.81

Integra Lifesciences Holdings Intrinsic Value: Projected FCF Historical Data

The historical data trend for Integra Lifesciences Holdings's Intrinsic Value: Projected FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Integra Lifesciences Holdings Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Intrinsic Value: Projected FCF

24.20

26.93

34.34

39.04

35.47

Integra Lifesciences Holdings Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Intrinsic Value: Projected FCF																39.04	38.77	37.16	35.58	35.47

Competitive Comparison

For the Medical Devices subindustry, Integra Lifesciences Holdings's Price-to-Projected-FCF, along with its competitors' market caps and Price-to-Projected-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Integra Lifesciences Holdings Price-to-Projected-FCF Distribution

For the Medical Devices & Instruments industry and Healthcare sector, Integra Lifesciences Holdings's Price-to-Projected-FCF distribution charts can be found below:

* The bar in red indicates where Integra Lifesciences Holdings's Price-to-Projected-FCF falls into.

Integra Lifesciences Holdings Intrinsic Value: Projected FCF Calculation

Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company.

The details of how we calculate the intrinsic value of stocks are described in detail here.

This method smooths out the free cash flow over the past 6-7 years, multiplies the results by a growth multiple, and adds a portion of Total Stockholders Equity.

Intrinsic Value: Projected FCF = ( Growth Multiple * Free Cash Flow (6 year avg) + 0.8 * Total Stockholders Equity (most recent) ) / Shares Outstanding (Diluted Average)

In the case of negative Total Stockholders Equity, the following formula is used (see Explanation section below for the reason):

Intrinsic Value: Projected FCF = ( Growth Multiple * Free Cash Flow (6 year avg) + Total Stockholders Equity (most recent) / 0.8 ) / Shares Outstanding (Diluted Average)

Add all the Free Cash Flow together and divide 6 will get Integra Lifesciences Holdings's Free Cash Flow(6 year avg) = $145.83.

Integra Lifesciences Holdings's Intrinsic Value: Projected FCF for today is calculated as

Intrinsic Value: Projected FCF	=	(Growth Multiple	*	Free Cash Flow (6 year avg)	+	Total Stockholders Equity (Dec23)	*	0.8)	/	Shares Outstanding (Diluted Average)
	=	(10.265723347005	*	145.83328	+	1587.884	*	0.8)	/	78.012
	=	35.47

Integra Lifesciences Holdings (NAS:IART) Intrinsic Value: Projected FCF Explanation

The growth multiple is capped between 8.35 and 17.74.

Total Stockholders Equity weighting is more art than science and it should always be revisited in more detail when researching a company. Weightings from 0% to 100% to more than 100% are possible. 80% was chosen as a happy median after taking the above ideas into consideration.

Integra Lifesciences Holdings's Price-to-Intrinsic-Value-Projected-FCF for today is calculated as

Price-to-Intrinsic-Value-Projected-FCF	=	Share Price	/	Intrinsic Value: Projected FCF
	=	28.68	/	35.473918208306
	=	0.81

Integra Lifesciences Holdings Intrinsic Value: Projected FCF Related Terms

Thank you for viewing the detailed overview of Integra Lifesciences Holdings's Intrinsic Value: Projected FCF provided by GuruFocus.com. Please click on the following links to see related term pages.

Integra Lifesciences Holdings (Integra Lifesciences Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Integra Lifesciences Holdings Corp (NAS:IART) » Definitions » Intrinsic Value: Projected FCF

Comparable Companies

Traded in Other Exchanges

IL3:Germany

Address

1100 Campus Road, Princeton, NJ, USA, 08540

Website

https://www.integralife.com

Integra Lifesciences Holdings Corp is a New Jersey-based medical equipment company focused on developing products for regenerative therapy, extremity orthopedics, and neurosurgical applications. The firm is organized into two primary segments: Codman specialty surgical and tissue technologies. Codman specialty surgical generates maximum revenue from its segmental operations. Integra serves Europe, Asia Pacific, and the rest of the world whilst it derives key revenue from domestic sales.

Executives

Chantal Veillon-berteloot	officer: EVP & CHRO	1100 CAMPUS ROAD, PRINCETON NJ 08540
Jeffrey Mosebrook	officer: SVP, Fin & PAO	311 ENTERPRISE DRIVE, PLAINSBORO NJ 08536
Lea Daniels Knight	officer: EVP & CFO	1100 CAMPUS ROAD, PRINCETON NJ 08540
Eric Schwartz	officer: Corp VP, Gen Counsel & Sec	C/O ERESEARCHTECHNOLOGY, INC., 1818 MARKET STREET, SUITE 1000, PHILADELPHIA PA 19103
Witte Jan De	director, officer: President & CEO	C/O RESMED INC., 9001 SPECTRUM CENTER BLVD., SAN DIEGO CA 92123
Michael J. Mcbreen	officer: Executive VP & President, CSS	1100 CAMPUS ROAD, PRINCETON NJ 08540
Harvinder Singh	officer: Exec VP & PRES, International	1100 CAMPUS ROAD, PRINCETON NJ 08540
Lisa Evoli	officer: Chief Human Resources Officer	311 ENTERPRISE DRIVE, PLAINSBORO NJ 08536
Raymond G. Murphy	director	14604 CARROLTON ROAD, ROCKVILLE MD 20853
Renee Wonlai Lo	director	1100 CAMPUS ROAD, PRINCETON NJ 08540
Glenn Coleman	officer: CVP, CHIEF FINANCIAL OFFICER	C/O DENTSLY SIRONA INC, 13320 BALLANTYNE CORPORATE PLACE, CHARLOTTE NC 28277
Tru St Partnership, L.p.	10 percent owner	795 EAST LANCASTER AVE., STE. 200, VILLANOVA PA 19085
Peter J Arduini	officer: President & COO	311 ENTERPRISE DRIVE, PLAINSBORO NJ 08536
Shaundra Clay	director	1100 CAMPUS ROAD, PRINCETON NJ 08540
Stuart Essig	director, officer: President and CEO	311 C ENTERPRISE DRIVE, PLAINSBORO NJ 08536